Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myelogenous Leukemia
The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
June 27th, 2008
Provid Pharmaceuticals, Inc. and The Leukemia & Lymphoma Society (LLS) today jointly announced the execution of a research agreement to advance the development of a treatment for acute myelogenous leukemia. Under the arrangement, LLS has contracted with Provid to supply expert medicinal chemistry services in support of an LLS-funded Specialized Center of Research (SCOR) grant at the University of Virginia under the direction of Prof. John Bushweller, Ph.D. "Provid's expertise adds a critical component to our SCOR program that will help advance our efforts from 'interesting laboratory results' to potential therapies," said Dr. Bushweller. ...
Source: Health Business Week (2008-06-27)
|
